BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38599922)

  • 1. Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review.
    Dima A; Vonk MC; Garaiman A; Kersten BE; Becvar R; Tomcik M; Hoffmann-Vold AM; Castellvi I; Jaime JT; Brzosko M; Milchert M; Krasowska D; Michalska-Jakubus M; Airo P; Matucci-Cerinic M; Bruni C; Iudici M; Distler J; Gheorghiu AM; Poormoghim H; Motta F; De Santis M; Parvu M; Distler O; Mihai C
    Eur J Intern Med; 2024 Jul; 125():104-110. PubMed ID: 38599922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia.
    Yamashita Y; Yamano Y; Muro Y; Ogawa-Momohara M; Takeichi T; Kondoh Y; Akiyama M
    Rheumatology (Oxford); 2022 Apr; 61(4):1709-1716. PubMed ID: 34282441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study.
    Miyake M; Matsushita T; Takehara K; Hamaguchi Y
    Int J Rheum Dis; 2020 Aug; 23(9):1219-1225. PubMed ID: 32662135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.
    Chang WS; Schollum J; White DH; Solanki KK
    Clin Rheumatol; 2015 Nov; 34(11):1921-7. PubMed ID: 26022620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.
    Minier T; Guiducci S; Bellando-Randone S; Bruni C; Lepri G; Czirják L; Distler O; Walker UA; Fransen J; Allanore Y; Denton C; Cutolo M; Tyndall A; Müller-Ladner U; Matucci-Cerinic M; ;
    Ann Rheum Dis; 2014 Dec; 73(12):2087-93. PubMed ID: 23940211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological profile of patients with systemic sclerosis.
    Wielosz E; Dryglewska M; Majdan M
    Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
    Faucher B; Stein P; Granel B; Weiller PJ; Disdier P; Serratrice J; Harlé JR; Durand JM; Frances Y; Guis S; Pham T; Bardin N; Sanmarco M
    Eur J Intern Med; 2010 Apr; 21(2):114-7. PubMed ID: 20206882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-related autoantibody profile in patients with systemic sclerosis.
    Liaskos C; Marou E; Simopoulou T; Barmakoudi M; Efthymiou G; Scheper T; Meyer W; Bogdanos DP; Sakkas LI
    Autoimmunity; 2017 Nov; 50(7):414-421. PubMed ID: 28749191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
    D'Aoust J; Hudson M; Tatibouet S; Wick J; ; Mahler M; Baron M; Fritzler MJ
    Arthritis Rheumatol; 2014 Jun; 66(6):1608-15. PubMed ID: 24577935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
    Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
    Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
    Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
    J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
    Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
    Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
    J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinuclear antibody-negative systemic sclerosis.
    Salazar GA; Assassi S; Wigley F; Hummers L; Varga J; Hinchcliff M; Khanna D; Schiopu E; Phillips K; Furst DE; Steen V; Baron M; Hudson M; Taillefer SS; Pope J; Jones N; Docherty P; Khalidi NA; Robinson D; Simms RW; Silver RM; Frech TM; Fessler BJ; Molitor JA; Fritzler MJ; Segal BM; Al-Kassab F; Perry M; Yang J; Zamanian S; Reveille JD; Arnett FC; Pedroza C; Mayes MD
    Semin Arthritis Rheum; 2015 Jun; 44(6):680-6. PubMed ID: 25578738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features of systemic sclerosis and association with antitopoisomerase-1 antibody and centromere pattern of antinuclear antibody].
    Bertazzi GR; de Toledo RA; de Godoy MF; Geraldino GC; Polizelli DV; Fernandes GC; Pedroso CL; dos Santos FG; de Assis TM
    Acta Reumatol Port; 2012; 37(1):9-17. PubMed ID: 22781510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis.
    Bonroy C; Van Praet J; Smith V; Van Steendam K; Mimori T; Deschepper E; Deforce D; Devreese K; De Keyser F
    J Immunol Methods; 2012 May; 379(1-2):53-60. PubMed ID: 22446156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serologic profile and mortality rates of scleroderma renal crisis in Italy.
    Codullo V; Cavazzana I; Bonino C; Alpini C; Cavagna L; Cozzi F; Del Papa N; Franceschini F; Guiducci S; Morozzi G; Ruffatti A; Ferri C; Giacomelli R; Matucci-Cerinic M; Valentini G; Montecucco C
    J Rheumatol; 2009 Jul; 36(7):1464-9. PubMed ID: 19487262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study.
    Rozman B; Cucnik S; Sodin-Semrl S; Czirják L; Varjú C; Distler O; Huscher D; Aringer M; Steiner G; Matucci-Cerinic M; Guiducci S; Stamenkovic B; Stankovic A; Kveder T
    Ann Rheum Dis; 2008 Sep; 67(9):1282-6. PubMed ID: 18063672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.
    Mendes C; Viana VST; Pasoto SG; Leon EP; Bonfa E; Sampaio-Barros PD
    Clin Rheumatol; 2020 Jan; 39(1):9-17. PubMed ID: 31065858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.